share_log

8-K/A: Current report (Amendment)

8-K/A: Current report (Amendment)

8-K/A：重大事件(修正)
美股SEC公告 ·  2024/08/09 05:05

Moomoo AI 已提取核心訊息

Ginkgo Bioworks reported Q2 2024 revenue of $56 million, down 30% YoY, with Cell Engineering revenue declining 20% to $36 million and Biosecurity revenue at $20 million. The quarter's operating loss was $223 million, including $38 million in stock-based compensation and $72 million in restructuring costs.The company has begun implementing its previously announced restructuring plan, with workforce reductions starting in June 2024 expected to achieve over $85 million in annualized savings by mid-2025. The plan includes consolidating office and laboratory operations into fewer locations, with facility consolidation actions targeted for completion in 2025.Despite restructuring, Ginkgo maintained its 2024 revenue guidance of $170-190 million, including $120-140 million from Cell Engineering and at least $50 million from Biosecurity. The company added 18 new programs in Q2, including its first Lab Data as a Service deals with a large tech company, while maintaining $730 million in cash and cash equivalents.
Ginkgo Bioworks reported Q2 2024 revenue of $56 million, down 30% YoY, with Cell Engineering revenue declining 20% to $36 million and Biosecurity revenue at $20 million. The quarter's operating loss was $223 million, including $38 million in stock-based compensation and $72 million in restructuring costs.The company has begun implementing its previously announced restructuring plan, with workforce reductions starting in June 2024 expected to achieve over $85 million in annualized savings by mid-2025. The plan includes consolidating office and laboratory operations into fewer locations, with facility consolidation actions targeted for completion in 2025.Despite restructuring, Ginkgo maintained its 2024 revenue guidance of $170-190 million, including $120-140 million from Cell Engineering and at least $50 million from Biosecurity. The company added 18 new programs in Q2, including its first Lab Data as a Service deals with a large tech company, while maintaining $730 million in cash and cash equivalents.
銀杏生物科技報告2024年第二季度營業收入爲5600萬美元，同比下降30%，電芯工程營業收入下降20%，爲3600萬美元，生物安全營業收入爲2000萬美元。該季度的運營虧損爲22300萬美元，包括3800萬美元的股票薪酬和7200萬美元的重組費用。該公司已經開始實施其先前宣佈的重組計劃，預計從2024年6月開始的員工裁減將於2025年中期實現超過8500萬美元的年度節省。該計劃包括將辦公室和實驗室的運營整合到更少的地點，設施整合措施預計在2025年完成。儘管進行了重組，銀杏仍然維持其2024年的營業收入指導在17000-19000萬美元，其中電芯工程預計收入在12000-14000萬美元，生物安全至少5000萬美元。該公司在第二季度增加了18個新項目，包括與一家大型科技公司的首個實驗室數據即服務協議，同時保持了73000萬美元的現金及現金等價物。
銀杏生物科技報告2024年第二季度營業收入爲5600萬美元，同比下降30%，電芯工程營業收入下降20%，爲3600萬美元，生物安全營業收入爲2000萬美元。該季度的運營虧損爲22300萬美元，包括3800萬美元的股票薪酬和7200萬美元的重組費用。該公司已經開始實施其先前宣佈的重組計劃，預計從2024年6月開始的員工裁減將於2025年中期實現超過8500萬美元的年度節省。該計劃包括將辦公室和實驗室的運營整合到更少的地點，設施整合措施預計在2025年完成。儘管進行了重組，銀杏仍然維持其2024年的營業收入指導在17000-19000萬美元，其中電芯工程預計收入在12000-14000萬美元，生物安全至少5000萬美元。該公司在第二季度增加了18個新項目，包括與一家大型科技公司的首個實驗室數據即服務協議，同時保持了73000萬美元的現金及現金等價物。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間